AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39402559 — intervention group
Group type: COMPARATOR
Intervention: All interventions
Number of subjects: 126
Study 39402581 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 1002
Study 39402581 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 1002
Study 39402603 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP-630
Number of subjects: 35
Study 39402603 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP-630-MS
Number of subjects: 35
Study 39402675 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 836880 40 mg, 360 mg, and 720 mg q3w
Number of subjects: 0
Study 39402675 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 836880 500 mg q3w
Number of subjects: 0
Study 39402688 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies including identifying care champions, changing record systems, ongoing training, audit and feedback, and changing physical structure/equipment.
Number of subjects: 9
Study 39402688 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient intervention including detection of elevated blood pressure, educational materials, lifestyle modification advice, and medication where needed.
Number of subjects: 9
Study 39402688 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies and patient intervention combined.
Number of subjects: 9
Study 39402877 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-food plant-based diet (WPBD) for 16 weeks
Number of subjects: 36
Study 39402877 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) instructed not to change their diet
Number of subjects: 36
Study 39402910 — intervention group
Group type: EXPERIMENTAL
Intervention: MINST + xHyA
Number of subjects: 42
Study 39402910 — intervention group
Group type: COMPARATOR
Intervention: MINST alone
Number of subjects: 42
Study 39403266 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% human serum albumin solution injected via the artery immediately after successful reperfusion (maximum dose 0.60 g/kg)
Number of subjects: 15
Study 39403266 — intervention group
Group type: COMPARATOR
Intervention: Endovascular treatment alone (ET cohort)
Number of subjects: 15
Study 39403397 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to whole grain foods over an extended period of time in a free-living situation.
Number of subjects: 0
Study 39403397 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study 39403556 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenabasum
Number of subjects: 20
Study 39403561 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of BNT162b2 vaccine
Number of subjects: 68
Study 39403626 — intervention group
Group type: EXPERIMENTAL
Intervention: Eftilagimod alpha (30 mg subcutaneously every 2 weeks for eight 3-week cycles and then every 3 weeks for up to 54 weeks) plus Pembrolizumab (200 mg intravenously every 3 weeks for up to 105 weeks)
Number of subjects: 36
Study 39403626 — intervention group
Group type: EXPERIMENTAL
Intervention: Eftilagimod alpha plus Pembrolizumab
Number of subjects: 36
Study 39403781 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical therapy, methotrexate, adalimumab, secukinumab, or guselkumab (effective treatment achieving PASI 90)
Number of subjects: 80
Study 39403781 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (20 participants)
Number of subjects: 80
Study 39403781 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating biomarkers of endothelial activation (ICAM-1, VCAM-1, E- and P-selectin, GDF-15, TRAIL)
Number of subjects: 80
Study 39403832 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence confocal microscopy (FCM) using the Histolog® scanner
Number of subjects: 31
Study 39403832 — intervention group
Group type: COMPARATOR
Intervention: Paraffin-embedded analysis (PA)
Number of subjects: 31
Study 39403832 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater agreement among four blinded pathologists
Number of subjects: 31
Study 39404123 — intervention group
Group type: EXPERIMENTAL
Intervention: Iptacopan 200 mg twice daily
Number of subjects: 0
Study 39404123 — intervention group
Group type: EXPERIMENTAL
Intervention: Iptacopan
Number of subjects: 0
Study 39404168 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) plus Care as Usual (CAU)
Number of subjects: 139
Study 39404168 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 139
Study 39404227 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0
Study 39404227 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide + ADT
Number of subjects: 0
Study 39404227 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide with other treatments (like docetaxel)
Number of subjects: 0
Study 39404790 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 30
Study 39404790 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 30
Study 39404994 — intervention group
Group type: EXPERIMENTAL
Intervention: Eblasakimab 400 mg
Number of subjects: 0
Study 39404994 — intervention group
Group type: EXPERIMENTAL
Intervention: Eblasakimab 600 mg
Number of subjects: 0
Study 39404994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39405026 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiolabelled exendin
Number of subjects: 14
Study 39405060 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide
Number of subjects: 1179
Study 39405060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1179
Study 39405104 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Telehealth Project (telehealth intervention)
Number of subjects: 19
Study 39405292 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Photobiomodulation
Number of subjects: 180
Study 39405292 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular Photobiomodulation
Number of subjects: 180
Study 39405292 — intervention group
Group type: COMPARATOR
Intervention: Placebo Local Photobiomodulation
Number of subjects: 180
Study 39405292 — intervention group
Group type: COMPARATOR
Intervention: Placebo Vascular Photobiomodulation
Number of subjects: 180
Study 39405373 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA polyzene F (PzF) stent followed by 14 days of DAPT
Number of subjects: 996
Study 39405373 — intervention group
Group type: COMPARATOR
Intervention: FDA-approved new-generation drug-eluting stent followed by 3 or 6 months of DAPT
Number of subjects: 996
Study 39405605 — intervention group
Group type: EXPERIMENTAL
Intervention: CIETAI combined with PD-1 inhibitor tislelizumab plus oxaliplatin, followed by standard concomitant chemoradiotherapy (capecitabine and 50.4 Gy radiation). Intravenous tislelizumab was administered for an additional two cycles.
Number of subjects: 38
Study 39405911 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 18
Study 39405911 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (DOX)
Number of subjects: 18
Study 39405911 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX) + Metformin (MET)
Number of subjects: 18
Study 39405978 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermidine trihydrochloride supplement at 40 mg/day
Number of subjects: 37
Study 39405978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 39406181 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality goggles (360° relaxing videos, 30 min per use, 3 days a week for 4 weeks)
Number of subjects: 44
Study 39406181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study 39406181 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality goggles
Number of subjects: 44
Study 39406392 — intervention group
Group type: EXPERIMENTAL
Intervention: iCer NIVO + IPI
Number of subjects: 42
Study 39406392 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative iCav NIVO (1-5-10 mg)
Number of subjects: 42
Study 39406392 — intervention group
Group type: EXPERIMENTAL
Intervention: iCav NIVO plus IPI
Number of subjects: 42
Study 39406392 — intervention group
Group type: COMPARATOR
Intervention: Historical pooled cohort of Belgian rHGG patients treated with anti-VEGF therapies
Number of subjects: 42
Study 39406403 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every 4 weeks
Number of subjects: 0
Study 39406403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39406449 — intervention group
Group type: EXPERIMENTAL
Intervention: Short term intensive insulin therapy (SIIT) followed by linagliptin 5 mg/day for 48 weeks
Number of subjects: 412
Study 39406449 — intervention group
Group type: EXPERIMENTAL
Intervention: Short term intensive insulin therapy (SIIT) followed by metformin 1000 mg/day for 48 weeks
Number of subjects: 412
Study 39406449 — intervention group
Group type: EXPERIMENTAL
Intervention: Short term intensive insulin therapy (SIIT) followed by combination linagliptin plus metformin for 48 weeks
Number of subjects: 412
Study 39406449 — intervention group
Group type: COMPARATOR
Intervention: Short term intensive insulin therapy (SIIT) followed by lifestyle modification alone for 48 weeks (control)
Number of subjects: 412
Study 39406613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadofaragene firadenovec
Number of subjects: 32
Study 39406630 — intervention group
Group type: EXPERIMENTAL
Intervention: U-SleepSQ model using 24/7 electroencephalography SubQ data
Number of subjects: 22
Study 39406630 — intervention group
Group type: EXPERIMENTAL
Intervention: U-SleepSQ model
Number of subjects: 22
Study 39406730 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus anlotinib hydrochloride
Number of subjects: 48
Study 39407122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided erector spinae plane block (ESPB)
Number of subjects: 80
Study 39407122 — intervention group
Group type: COMPARATOR
Intervention: Wound infiltration (WI)
Number of subjects: 80
Study 39407194 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR (Neutrophil-to-Lymphocyte Ratio)
Number of subjects: 443
Study 39407194 — intervention group
Group type: EXPERIMENTAL
Intervention: PLR (Platelet-to-Lymphocyte Ratio)
Number of subjects: 443
Study 39407194 — intervention group
Group type: EXPERIMENTAL
Intervention: Plateletcrit
Number of subjects: 443
Study 39407194 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet count
Number of subjects: 443
Study 39407194 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR cutoffs
Number of subjects: 443
Study 39407194 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of inflammation
Number of subjects: 443
Study 39407204 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased perceived threat of COVID-19
Number of subjects: 500
Study 39407204 — intervention group
Group type: COMPARATOR
Intervention: Anxiety and depression (controlled for in analysis)
Number of subjects: 500
Study 39407206 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruxism patients (64)
Number of subjects: 128
Study 39407206 — intervention group
Group type: COMPARATOR
Intervention: Non-bruxism patients (64)
Number of subjects: 128
Study 39407226 — intervention group
Group type: EXPERIMENTAL
Intervention: Elite endurance runners and elite sprinters
Number of subjects: 188
Study 39407226 — intervention group
Group type: COMPARATOR
Intervention: Untrained individuals
Number of subjects: 188
Study 39407230 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia at 33°C
Number of subjects: 600
Study 39407230 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (target < 37.8°C)
Number of subjects: 600
Study 39407238 — intervention group
Group type: EXPERIMENTAL
Intervention: DIDE mobile application
Number of subjects: 24
Study 39407247 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 120
Study 39407247 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOE
Number of subjects: 120
Study 39407247 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoMTA™
Number of subjects: 120
Study 39407247 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine™
Number of subjects: 120
Study 39407315 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (MgSO4) iontophoresis plus conventional physical therapy program
Number of subjects: 75
Study 39407315 — intervention group
Group type: EXPERIMENTAL
Intervention: High-power pain-threshold ultrasound (HPPT-US) plus conventional therapy
Number of subjects: 75
Study 39407315 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 75
Study 39407325 — intervention group
Group type: EXPERIMENTAL
Intervention: mannitol-potentiated low-dose amikacin
Number of subjects: 90
Study 39407325 — intervention group
Group type: COMPARATOR
Intervention: ceftriaxone or amikacin standard dose
Number of subjects: 90
Study 39407334 — intervention group
Group type: COMPARATOR
Intervention: Treat-to-target-driven fixed dose retreatment strategy (usual care group) - retreated with fixed rituximab doses (1 × 1000 mg IV) in case of loss of disease control (DAS28-CRP ≥ 3.2)
Number of subjects: 134
Study 39407334 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed interval disease-activity guided dose optimisation strategy (experimental group) - 24-weekly rituximab treatment with tapering doses: 1 × 1000 mg IV (maximal dose), 1 × 500 mg IV, and 1 × 200 mg IV (minimal dose)
Number of subjects: 134
Study 39407334 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed interval disease-activity guided dose optimisation strategy (experimental group)
Number of subjects: 134
Study 39407334 — intervention group
Group type: COMPARATOR
Intervention: Treat-to-target-driven fixed dose retreatment strategy (usual care group)
Number of subjects: 134
Study 39407365 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical method using a rotary master apical file
Number of subjects: 60
Study 39407365 — intervention group
Group type: COMPARATOR
Intervention: Chemomechanical method using an endoactivator to sonically agitate the endodontic irrigant
Number of subjects: 60
Study 39407366 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural and kinesthetic awareness sessions (experimental group B)
Number of subjects: 52
Study 39407366 — intervention group
Group type: COMPARATOR
Intervention: Routine physical therapy (control group A)
Number of subjects: 52
Study 39407381 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercises
Number of subjects: 22
Study 39407381 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic exercises
Number of subjects: 22
Study 39407408 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led integrated care intervention
Number of subjects: 69
Study 39407408 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study 39407731 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Digital Ostomy Device
Number of subjects: 0
Study 39407731 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39407979 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 ARDS
Number of subjects: 0
Study 39407979 — intervention group
Group type: COMPARATOR
Intervention: Non-COVID-19 ARDS
Number of subjects: 0
Study 39408038 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39408203 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Ketogenic Diet (VLCKD) for 20 weeks
Number of subjects: 20
Study 39408354 — intervention group
Group type: EXPERIMENTAL
Intervention: 2'-Fucosyllactose (3 g/d)
Number of subjects: 41
Study 39408358 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency Tart Cherry Powder supplementation with a purine-rich meal
Number of subjects: 0
Study 39408358 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39408601 — intervention group
Group type: EXPERIMENTAL
Intervention: Taldefgrobep alfa as an adjunct to SMN upregulators
Number of subjects: 0
Study 39408601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39409993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer Patient Empowerment Program (CancerPEP) without HRV biofeedback monitor
Number of subjects: 104
Study 39409993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer Patient Empowerment Program (CancerPEP) with HRV biofeedback monitor
Number of subjects: 104
Study 39409993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer Patient Empowerment Program (CancerPEP) for breast cancer subgroup
Number of subjects: 104
Study 39409993 — intervention group
Group type: COMPARATOR
Intervention: Usual care without intervention (control group for future trial)
Number of subjects: 104
Study 39410716 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplements (T3)
Number of subjects: 290
Study 39410716 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplements (T2)
Number of subjects: 290
Study 39410716 — intervention group
Group type: EXPERIMENTAL
Intervention: Both magnesium and potassium supplements (T4)
Number of subjects: 290
Study 39410716 — intervention group
Group type: COMPARATOR
Intervention: Control/placebo (T1)
Number of subjects: 290
Study 39410736 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP+ intervention
Number of subjects: 7
Study 39410977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 24
Study 39410977 — intervention group
Group type: COMPARATOR
Intervention: Cognitive rehabilitation (Control)
Number of subjects: 24
Study 39411184 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iTBS targeting the right DLPFC
Number of subjects: 96
Study 39411184 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iTBS targeting the left LPC
Number of subjects: 96
Study 39411184 — intervention group
Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 96
Study 39411190 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in the hypoattenuating region of the blend sign (CHB group)
Number of subjects: 183
Study 39411190 — intervention group
Group type: COMPARATOR
Intervention: No changes in the hypoattenuating region of the blend sign (NHB group)
Number of subjects: 183
Study 39411383 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.05 mg/kg; i.v.) + oral pramipexole (0.25 mg)
Number of subjects: 19
Study 39411383 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.1 mg/kg; i.v.) + oral placebo
Number of subjects: 19
Study 39411812 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg plus carboplatin-paclitaxel (four to six cycles) followed by pembrolizumab 400 mg (six cycles)
Number of subjects: 281
Study 39411812 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus carboplatin-paclitaxel (four to six cycles) followed by placebo (six cycles)
Number of subjects: 281
Study 39411974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous secukinumab (Cosentyx®) at a dosage of 3 mg/kg every 4 weeks (q4w)
Number of subjects: 2
Study 39411974 — intervention group
Group type: COMPARATOR
Intervention: Intravenous secukinumab (Cosentyx®) at a dosage of 1.75 mg/kg every 4 weeks (q4w)
Number of subjects: 2
Study 39411994 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive HPI
Number of subjects: 91
Study 39411994 — intervention group
Group type: COMPARATOR
Intervention: Invasive HPI
Number of subjects: 91
Study 39412495 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Parenting Intervention (HIP)
Number of subjects: 106
Study 39412495 — intervention group
Group type: COMPARATOR
Intervention: Lower-Intensity Parenting Intervention (LIP)
Number of subjects: 106
Study 39412509 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous semaglutide 2.4 mg
Number of subjects: 800
Study 39412509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 39412613 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-task deep-learning model for automated segment-level coronary artery calcium scoring
Number of subjects: 1514
Study 39412619 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Administration Device (CAD)
Number of subjects: 3
Study 39412628 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin pamoate 22.5 mg (day 1 and month 6)
Number of subjects: 66
Study 39412672 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally designed intervention with gamification and social support
Number of subjects: 31
Study 39412672 — intervention group
Group type: COMPARATOR
Intervention: Control group (weekly updates only)
Number of subjects: 31
Study 39412732 — intervention group
Group type: EXPERIMENTAL
Intervention: mySugr
Number of subjects: 28
Study 39412732 — intervention group
Group type: COMPARATOR
Intervention: usual care (bolus calculator, five face-to-face visits)
Number of subjects: 28
Study 39412778 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR
Number of subjects: 1891
Study 39412778 — intervention group
Group type: COMPARATOR
Intervention: FFR
Number of subjects: 1891
Study 39412806 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-extremity approach (radial artery diagnostic access and upper-arm vein for temporary pacing lead placement)
Number of subjects: 238
Study 39412806 — intervention group
Group type: COMPARATOR
Intervention: Lower-extremity approach (femoral artery diagnostic access and femoral vein for temporary pacing lead placement)
Number of subjects: 238
Study 39412806 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-extremity approach
Number of subjects: 238
Study 39412806 — intervention group
Group type: COMPARATOR
Intervention: Lower-extremity approach
Number of subjects: 238
Study 39412840 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced health education intervention
Number of subjects: 20
Study 39412840 — intervention group
Group type: COMPARATOR
Intervention: Basic health education alone
Number of subjects: 20
Study 39412860 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary home-based rehabilitation program (32 sessions for physical therapy, 8 sessions for occupational therapy, 4 sessions for nutrition, 8 sessions for psychology, and 4 sessions for nursing and podiatry over 4 months)
Number of subjects: 270
Study 39412860 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary home-based rehabilitation program
Number of subjects: 270
Study 39412869 — intervention group
Group type: EXPERIMENTAL
Intervention: LIVIA 2.0 (active arm)
Number of subjects: 62
Study 39412869 — intervention group
Group type: COMPARATOR
Intervention: LIVIA 1 (control arm)
Number of subjects: 62